Abstract Review Article
IntRoductIon
Legionella pneumophila was first discovered in 1976, following a sudden epidemic of fever with pneumonia among the delegates of the American Legion conference in Philadelphia, USA. The US Centers for disease control and Prevention (CDC) had sent a team of scientists led by David Fraser for investigating the outbreak and by December 1976, Joseph Mc Dade isolated a new bacterium from guinea pigs exposed with infected lung tissue of a patient. The pathogen was named Legionella for its association with the American veterans who were the first victims. [1] The genus Legionella comprises >50 species; among these around 30 species can infect humans producing infections mainly in the lower respiratory tract (LRT). Legionella spp. are aerobic, Gram-negative, nonspore forming gamma proteobacteria with strict growth requirements. Legionella are ubiquitous in freshwater environments including rivers, lakes, streams, fountains and hot springs where they survive in association with complex biofilm communities and can replicate inside various protozoan hosts. Legionella spp. survive in aquatic systems having a temperature range of 25°C-37°C but can also withstand temperatures of >50°C for several hours and may propagate at low temperatures of <20°C. [1, 2] Pneumonia attributable to any Legionella species is known as Legionnaires' disease (LD) which is mostly transmitted via inhalation of infected aerosols. Other modes of transmissions are microaspiration of contaminated water in hospital settings and direct contact with Legionella in open wounds during surgery. [1] [2] [3] Nature of infectious form, infective dose, etc., is still not known. Different strains of Legionella vary clearly in their virulence. Among all species, L. pneumophila is the most pathogenic accounting 90% of reported cases worldwide and L. pneumophila serogroup 1 (Lp1) is the most virulent serogroup causing >80% of LD. [1, 4] Legionella spp. are intracellular pathogens and in lungs, they infect mononuclear cells (alveolar macrophages). In addition to a normal phagocytic process, phagocytosis of L. pneumophila also occur by a unique mechanism (engulfment within a pseudopod coil) termed as coiling phagocytosis.
legIonnAIRes' dIseAse: clInIcAl pResentAtIons
Clinical manifestations of Legionella infections include fever with pulmonary involvement (LD) or without pneumonia (Pontiac fever) and an extrapulmonary infection. [5] LD occurs, in the form of community-acquired pneumonia (CAP) that might clinically resemble other bacterial pneumonias. Symptoms range from mild infection to severe life-threatening pneumonia requiring hospital admission. The incubation period for LD is variable (2-14 days); the symptoms of LD include: fever at >38.8°C (67%-100%), cough (41%-92%), chills (15%-77%), dyspnoea (36%-56%), neurological abnormalities (38%-53%), myalgia or arthralgia (20%-43%), loose stools (19%-47%), chest pain (14%-50%), headache (17%-43%) and nausea or vomiting (9%-25%). [4] [5] [6] [7] Legionella may spread to internal organs via the blood and the lymphatics involving liver, kidney, spleen, heart, bone marrow, lymph nodes, gastrointestinal tract and central nervous system. [4] Diarrhoea, nausea, vomiting and abdominal pain are the common gastrointestinal symptoms. Neurological findings include headache, seizures and focal neurological deficits. [4, 8] In immunosuppressed individuals, the most common clinical presentation of LD is pneumonia, which may disseminate to other parts of the body. [9] The laboratory findings in LD are non-specific including hyponatraemia, elevated serum creatine kinase, myoglobinuria, leucocytosis with relative lymphopenia, high erythrocyte sedimentation rate and C-reactive protein levels. [10] The chest X-ray of LD show unilobar, patchy infiltrates progressing to consolidation; and pleural effusion is evident in 15%-50% of the individuals. In immunosuppressed patients round nodular opacities is a prominent finding and cavitations is seen in about 10% of the cases. [11] Pontiac fever is non-pneumonic disease associated with exposure to Legionella bacteria. [10, 12] legIonellA And legIonnAIRes' dIseAse: globAl epIdemIology, IncIdence And summARy of outbReAks
The global incidence of LD is unknown; it is under-reported in many countries mainly due to lack of awareness, scarcity of diagnostics and active LD surveillance systems. It is estimated that LD accounts for 2%-9% of cases of CAP worldwide. [4, 10] Legionnaire's disease is a notifiable disease in the USA and approximately 10,000-20,000 cases of LD occur each year in the United States. Reports from the USA point out 192% increase in the crude national incidence of LD, escalating from 3.9 cases per million inhabitants in 2000 to 11.5 cases per million inhabitants in 2009.
[13] This is mainly due to a sharp increase in diagnostic testing for LD, changes in case reporting methods and enlargement of the susceptible population. LD was confirmed using urinary antigen testing (UAT) in 97% of cases, and only 5% were diagnosed by culture.
Majority of LD cases were occurring during summer and early autumn showing a seasonal variation. The disease affects usually males >50 years of age having lung diseases or immunosuppression. Susceptibility of disease is also associated with old age, smoking, alcohol misuse, recent overnight travel, underlying medical conditions including diabetes, malignancies, HIV infection and end-stage renal diseases. [13] [14] [15] LD surveillance data from 20 states and a large metropolitan area from US in 2015 showed that health care associated LD cases were reported from 72 centres; and infections were fatal in one-fourth of the individuals. [16] LD cases reported to the European LD surveillance network were 4000-5000 in 2011; and the disease prevalence was 9.7 cases per million inhabitants. Afterward, between 2011 and 2015, 29 countries reported 30,532 LD cases to European Centers for Disease Control and Prevention. Among the European Union member countries, France, Germany, Italy, and Spain accounted for 70.3% of all reported cases. [1, 4, 14] In the USA and Europe, Lp1 is responsible for 70%-92% of cases and this serogroup account for 50% of LD cases in Australia. Other serogroups and species including L. pneumophila serogroup 6, L. longbeachae, L. micdadei, L. bozemanii etc., account for most of the remaining cases. In Australia and New Zealand, 30%-55% of reported LD cases are caused by L. longbeachae. LD is associated with substantial CAP severity and higher fatality rates (up to 30%) than other atypical pathogens. [17, 18] Outbreaks of LD in hotels, cruise ships, office buildings and health-care facilities have been reported. [19] [20] [21] Notable worldwide outbreaks of LD from 1976 to 2017 are depicted in Table 1 .
lAboRAtoRy detectIon of LegioneLLa spp. And legIonnAIRes' dIseAse Legionella spp. require special media and preferably pre-treatments (heat or acid) for growth. Culturing LRT specimen on selective media; buffered charcoal yeast extract agar is the gold standard and is the most specific method (specificity near 100%) for detection of L. pneumophila. [1, 22] Isolation of Legionella from clinical specimens allows epidemiological typing possible, thereby providing valuable data for control and prevention of further cases. Monoclonal direct fluorescent antibody (DFA) staining is a rapid method for detecting Legionella in respiratory secretions and tissue sample. At present, DFA is not widely used for Legionella diagnosis due to limitations in sensitivity and specificity. [1, 2, 23] Detection of soluble antigen in urine provides rapid qualitative detection of Legionella infections. At present, the UAT is available as a card/strip based immunochromatographic assay (Binax NOW Legionella urinary antigen test) that is easy to perform and having a turnaround time of 15 min. The captured antibody used in these assays is specific for Lp1; hence solely depending UAT can create a blind spot for LD caused by non-Lp1 strains. [4, 24] Concentrating the urine sample improves the sensitivity of antigen detection, but prolonged storage of specimens may hamper the test performance due to degradation of Legionella urinary antigen.
Serologic tests (indirect immunofluorescence assay [IFA] and enzyme-linked immunosorbent assays (ELISA) are valuable for epidemiological investigations, but the requirement of a convalescent sample for testing has limited the utility of these tests in patient treatment. The diagnosis is based on a four-fold increase in antibody titre to 1:128 or more between acute and convalescent-phase serum samples taken 4-8 weeks apart. Challenges in serological assays are cross-reactivity among Legionella spp. and non-Legionella bacteria; besides a proportion of people having LD do not have detectable seroconversion. [1, 2, 4, 25] Nucleic acid amplification tests (NAAT) allows specific amplification of Legionella DNA, report results within a short time frame and can detect all Legionella spp. and serogroups. When testing a LRT specimen, polymerase chain reaction (PCR) offer sensitivity equal to or greater than culture (80%-100%). Legionella DNA can be detected in urine, serum and leukocyte samples but sensitivity is variable (30%-86%). Sensitivity of molecular assays is likely to increase when samples are collected in the early course of the infection. [26] Currently, real-time PCR is considered as the molecular method of choice for detecting Legionella infections providing sensitivity, specificity and rapid results. CDC has developed multiplex real-time PCR assays for detecting Legionella spp., L. pneumophila, Lp1 and other clinically important non-pneumophila species such as L. anisa, L. bozemanii, L. longbeachea and L. micdadei. [1, 27, 28] Summary of laboratory detection of Legionella spp. and LD is depicted in [29] Subsequent environmental screening for Legionella at that time showed 76% positivity among the water samples tested. This was the first report of isolation of L. pneumophila in India. Later on, [31] These reports suggested that L. pneumophila can be one important cause of CAP and warranted empirical treatment with macrolides while treating patients having pneumonias.
Detection rates in clinical specimens, 2000-2010
Few studies based on serologic tests were conducted during this period to detect L. pneumophila in CAP patients. Chaudhry et al. in 2010 reported a total seropositivity of 27.43% by ELISA; anti L. pneumophila IgG, IgM and IgA positivities were 7.96%, 15.92% and 11.50%, respectively. L. pneumophila antigenuria (microwell ELISA) was positive in 17.69% of individuals and there was no culture positivity. [32] Anbumani et al. during the same period had reported isolation rate of 2.55% for Legionella spp. from clinical specimens in Tirupati, South India. [33] The study did not use other tests including UAT and DFA staining for Legionella detection. However, these reports confirmed that Legionella spp. is not so uncommon in India.
Legionella detection rates in clinical specimens, 2010 to present
During 2014, Chaudhry et al. reported L. pneumophila infection causing fatality in an immunocompromised patient undergoing treatment for sarcoidosis. The authors used PCR targeting 16S r RNA gene of Legionella along with UAT for rapid detection of the pathogen. [34] This was the first known fatal case due to L. pneumophila from India. Afterwards, Angrup et al., in 2016 detected L. pneumophila infections by real-time PCR (targeting mip gene), PCR and serology; and the positivity's were 6%, 4.4% and 23%, respectively. [35] Chaudhry et al. investigated the role of atypical pathogens including L. pneumophila in CAP patients in a multi centric study involving three major hospitals (All India Institute of Medical Sciences, VMMC and Safdarjung Hospital and Vallabhbhai Patel Chest Institute) in New Delhi. Legionella infection was detected by PCR and UAT in one patient; whereas 11% of the patients showed seropositivity by IgM ELISA. [36] The study underscored the utility of multiple laboratory assays (PCR, culture, UAT and serology) for Legionella detection.
Changing patterns of Legionella diagnosis in India
Initially, most of the studies reported from India used culture, serology and DFA staining for LD detection; [29] [30] [31] [32] [33] but recently, there was a shift towards NAATs including PCR and real-time PCR. [33] [34] [35] [36] Angrup et al. used real-time PCR assays to detect Legionella in an early course before antibodies develops. [35] Notably, PCR targeting Pan Legionella spp. can detect infections caused by all Legionella strains. However in a developing country like India Legionella PCR is available only in few reference laboratories that use either an in-house assay or commercial kits.
Similarly, the use of UAT for Legionella detection has also increased significantly in recent times. Para RA et al., in 2018 detected L. pneumophila in 17.5% of CAP patients by UAT. [37] Antigenuria in Legionella infections can be detected shortly after the onset of clinical symptoms (2-3 days) and the antigen may be excreted for several days to >10 months, even during antibiotic treatment and after disease resolution. Type of specimens and diagnostic tests for detecting Legionella infections: Lower respiratory tract secretions, urine and blood samples can be collected and diagnosis of LD should be done by a panel of tests including culture, urinary antigen detection, serological assays and nucleic acid amplification test. Legionella infection in extrapulmonary sites including soft tissues, synovial fluid and dissemination via blood to internal organs such as spleen, heart, lymph node is very rare. Routine testing of specimens from these sites are not recommended.
Application of UAT along with PCR can detect LD rapidly, but it is to be noted that decrease in culture-based diagnosis may limit the detection of infections due to non-Lp1 strains. Besides, it is impossible to study the epidemiology of LD in detail without clinical isolates. Altogether when Legionella infection is suspected, UAT, PCR and culture should be performed; so that rapid diagnosis of Lp1, other strains of Legionella and availability of an isolate will be accomplished.
Clinical patterns of Legionnaires' disease in Indian patients
The exact incidence of LD is not known in India due to lack of: awareness, common disease definitions, diagnostic methods and reporting of cases. Due to the absence of national-level active LD surveillance systems, disease prevalence, seasonality, etc., are not clear in this country. However, most of the reported cases from India were sporadic and not associated with a known outbreak or possible cluster. Mostly, studies were conducted in patients having CAP, and hospital-acquired LD cases were so far not reported from this country.
Similar to reports from the USA and Europe studies from India also indicated that LD affect usually males >50 years of age, and in most instances, risk factors in patients including smoking and alcohol consumption were identified. Underlying medical conditions such as chronic obstructive airway disease, bronchial asthma, malignancy, diabetes mellitus, hypertension and end-stage renal disease were reported in our patient's population.
Fever and respiratory symptoms including cough, dyspnoea, chest pain and wheezing were the most common findings among patients with LD by any detection methods. Chaudhry et al. in 2000 reported the presence of extrapulmonary symptoms such as diarrhoea, abdominal pain and headache in Legionella seropositive cases; but such significant findings were not evident in successive studies. Gastrointestinal symptoms such as diarrhoea, abdominal pain and vomiting were noted frequently in association with Legionella infection. In addition, neurological symptoms due to Legionella spp. including disorientation, headache, drowsiness, confusion and coma were reported by Panagariya et al. in 2011. [38] Positive chest X-ray findings were noted in 75%-80% of LD cases diagnosed by serology and/or PCR. Consolidations and infiltrations were the most common radiological abnormalities seen in patients with LD.
The fatality rate of Legionella infection was unknown in most of these studies. However, Chaudhry et al. in 2014 have reported a fatal case due to Legionella causing infection complicated by renal failure in an immunocompromised patient. The patient was presented with systemic and respiratory symptoms along with bilateral infiltrations and nonspecific laboratory findings such as leucocytosis and hyponatraemia. Even though Legionella infection was detected and treated in the early course; the patient died eventually due to LD accompanied with sepsis and renal failure. [34] In general, the pulmonary manifestations of Legionella CAP are non-specific; similarly, the radiographic and laboratory findings seen in LD may overlap with other typical and atypical pulmonary pathogens. Hence, it is difficult to distinguish LD from other atypical pathogens including Mycoplasma pneumoniae and Chlamydophila pneumoniae and typical pneumonia on the basis of these criteria.
Detection of Legionella from environmental reservoirs in India, 1991-2017
Understanding the epidemiology of Legionella infection is obvious for making decisions about whether to test for Legionella infections and what tests have to be used in a geographical region. Legionella spp. are omnipresent in both natural and humanmade aqueous environments. Rapid monitoring of suspected hospital and environmental water systems for L. pneumophila is essential for risk assessment, to detect possible sources of infection and to prevent further cases. Few studies from India investigated the presence of Legionella in the water distributions systems of health-care facilities. Agrawal et al. in 1992 tested water samples from cooling towers, respirator-humidifier, etc., and reported a culture positivity of 76% for Legionella spp. [29] Later on, in 2010, Anbumani et al. detected L. pneumophila in 33.3% of water samples from hospital outlets by culture and biochemical identification. [39] The presence of these markers were evident in most of the isolates indicating the virulence of these strains to cause infections in individuals. Successive proactive environmental surveillance by Chaudhry et al. in 2017 reported the presence of Lp1 in 15.2% of water samples tested in a tertiary healthcare center in New Delhi. The authors used culture for isolation of Legionella spp.; and Lp1 was identified by real-time PCR targeting wzm gene. The study was useful for formulating infection control strategies to eradicate Legionella spp. in that setting. [40] These studies provided new information on the extent of Legionella colonisation in few health-care facilities in India, provided baseline data for measuring the effectiveness of intervention strategies and demonstrated the presence of genes encoding pathogenic potential in Legionella isolates. Clinical and environmental studies regarding Legionella spp. and LD from India are listed in Table 3 .
stAtus of LegioneLLa ReseARch In IndIA
Research work involving Legionella spp. has a vast potential to grow in developing countries such as India. The focus is needed to assess the disease burden, factors affecting the susceptibility in our population, to identify potential sources of infection and to understand the difference in the virulence of strains. Multicentric studies are needed in this country to estimate the incidences of LD, to document the morbidity and mortality and the economic burden associated with Legionella infections. In addition, Legionella risk assessment should be implemented in different environmental and clinical settings and optimum methods for environmental control of this pathogen has to be developed.
Disease caused by Legionella spp. still remains to be noticed as a public health problem in India. Sporadic cases go unnoticed and are overshadowed by burden caused by other diseases including tuberculosis, bacterial, and viral pneumonias. Hence, research to upgrade the diagnostic accuracy of Legionella tests is also needed; such tests should be standardised and used routinely in all patients with pneumonia. Application of molecular tools such as real-time PCR can be implemented for detecting Legionella spp. in our population so that LD will be diagnosed rapidly to meet patient management.
Studies regarding the environmental reservoirs of L. pneumophila have been reported from India, but more focus has to be given for understanding the epidemiology of LD in this country. There is a lacuna in phenotypic and genotypic characterisation and sequence-based typing data. Studies mentioning the antimicrobial susceptibilities of Legionella strains were reported from few countries, but such studies were not yet conducted in India. As L. pneumophila has the potential to become resistant to certain classes of drugs including macrolides and fluoroquinolones, resistance in clinical and environmental strains should be evaluated systematically.
Data suggested that few strains of Legionella are likely to cause infection than many others in human; hence, studies have to be conducted to investigate the environmental distribution of strains and to identify virulence markers in Legionella isolates. At present, advanced techniques such as next-generation sequencing are in the arsenal of researchers and application of such methods could help to explore genotypic factors in the causation of LD. As outbreaks are mostly associated with certain human-made aquatic sources, infection by Legionella spp. is considered as preventable. However, basic research on certain ecological parameters is underexplored.
Ecological parameters that influence L. pneumophila to colonize a water system includes the presence of a suitable microbial consortium such as protozoa and other bacterial species, [41, 42] presence or absence of divalent cations and nanoparticles, [43, 44] availability of organic carbon content, etc. [45] Optimal temperature of the water system, relative humidity of the climate, [46] [47] [48] flow conditions of the plumbing systems [49, 50] and the intrinsic capacity of the strain for quorum sensing is also important. [51, 52] In resource limited settings, it may not be possible to study all the above-mentioned parameters. To begin with, the combination of temperature and humidity may [53] Although there are no seasonal predilections for Legionella outbreak to occur, all through the year there are specific months which are optimal for the proliferation and spreading of the bacterium which differs with geographical locations. Besides, dormant or viable but non-cultivable forms of the bacterium can persist, [54] but they may occur only during unfavourable conditions where the numbers are not enough to cause an infection or outbreak. For public buildings, health-care settings, hotels and other institutions the recommendations provided by CDC can be followed regarding detection of Legionella spp. from environmental water samples. [55] Procedures for isolation and identification of Legionella spp. from environmental reservoirs are summarised in Figure 2 . Further confirmation shall be done by nucleic acid amplification tests and sub typing of isolates is possible using monoclonal antibodies. In the Figure 2 , swabs are dipped in initial water samples collected (5 ml) and 0.2 ml of samples can be directly plated on to BCYE agar; presumptive identification of Legionella spp.; confirmation and typing can be done as mentioned above tReAtment And pReventIon of legIonnAIRes' dIseAse As Legionella are intracellular pathogens, antibiotic should be bioactive within the cells, therefore certain classes including beta-lactams and aminoglycosides are ineffective. Macrolides, doxycycline, tetracyclines, ketolides and fluoroquinolones are proved to be effective against Legionella spp. The mainstay of anti-Legionella therapy in healthy as well as immunocompromised individuals is azithromycin and fluoroquinolones. [4, 56] Rifampicin is having good activity against Legionella spp. both in vitro and in vivo models, but this drug is recommended only as a part of combination therapy. Duration of treatment recommended by IDSA/ATS is 5-14 days, but the course is shorter for azithromycin due to its long half-life. [4, 56, 57] As LD is generally not transmitted from person-to-person (except a case reported in 2016; which can be a probable person-to-person transmission), [58] infections can be prevented by proper maintenance of water systems in buildings and health-care facilities. Nosocomial legionellosis can be prevented by environmental monitoring (routine culturing of potable and non-potable water samples for Legionella) in hospitals even in the absence of reported LD cases. Once the bacteria is detected, the hospitals should follow one reliable disinfection method such as superheating the water to 70°C-80°C and flushing, installation of copper-silver ionisation units, hyperchlorination (concentration 2-6 ppm) and installation of point-of-use filters, etc. [10, 59, 60] conclusIons LD is undoubtedly considered as an infection that is under reported and under diagnosed. Physicians should be aware of these infections and should include LD in the differential diagnosis of patients with pneumonias. Legionella infection can be suspected in patients when there is a lung finding with or without extrapulmonary features and suboptimal response to aminopenicillins. Specific diagnostic tests including culture, urinary antigen detection, NAAT and antibody detections should be performed to verify the diagnosis. With limited resources, developing nations including India has a long road to travel to know the disease burden caused by these bacteria. Identification of environmental niches of Legionella, improvements in risk assessment, proper detection and control of cases, identification of demographic changes and new risk factors in our patient population need high priorities.
''On the summer of seventy-six, I got a name only to sing some veterans' fame, Every corner I took the blame, like you never played the vexing game.
Little aerosols made the incident and your ailing was a mere accident.''
-The Summer of seventy-six-Legionella pneumophila monologue.
[61]
